Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCA | P06881 | 5/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | CALCRL | Q16602 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1435426 | 0.98 | CALCA (0.49) | CALCABACE1OPRM1CALCRLNPC1 | |
| Hydrochloric Acid SCHEMBL439460 | 0.98 | CALCA (0.49) | CALCABACE1OPRM1CALCRLNPC1 | |
| Hydrochloric Acid SCHEMBL1436147 | 0.98 | CALCA (0.49) | CALCABACE1OPRM1CALCRLNPC1 | |
| SCHEMBL30721785 | 0.94 | CALCA (0.47) | CALCABACE1OPRM1CALCRLOTUD7B | |
| SCHEMBL16235885 | 0.90 | CALCA (0.46) | CALCACALCRLNPC1OTUD7BCYP1A2 | |
| SCHEMBL15699749 | 0.87 | CALCA (0.44) | CALCACALCRLNPC1OTUD7BCYP1A2 | |
| SCHEMBL30087869 | 0.87 | CALCA (0.44) | CALCACALCRLNPC1 | |
| SCHEMBL15999444 | 0.87 | CALCA (0.44) | CALCACALCRLNPC1 | |
| SCHEMBL31456516 | 0.87 | CALCA (0.44) | CALCACALCRLNPC1OTUD7BCYP1A2 | |
| SCHEMBL30087880 | 0.85 | CALCA (0.43) | CALCACALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024046223-A1 | INDAZOLE FORMAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF | 熙源安健医药（上海）有限公司 | 2024-03-07 | — | — | WO | disclosed |
| CN-117624191-A | Indazole carboxamide derivatives, preparation method and application thereof | 熙源安健医药（上海）有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | RIKEN (JP) | 2022-08-16 | — | — | US | disclosed |
| US-20200172554-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2020-06-04 | — | — | US | disclosed |
| EP-2379529-B1 | CGRP-ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2015-06-10 | — | — | EP | disclosed |
| US-8952014-B2 | Pyrimidine derivatives which are CGRP—antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-10 | — | — | US | disclosed |
| US-20140275017-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275017-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8778957-B2 | CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778957-B2 | CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-07-15 | — | — | US | disclosed |
| EP-1802637-B1 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2008085317-A1 | BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| US-20080113966-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-05-15 | — | — | US | disclosed |
| US-20080113966-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-05-15 | — | — | US | disclosed |
| US-20080070899-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-03-20 | — | — | US | disclosed |
| US-20080070899-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-03-20 | — | — | US | disclosed |
| US-20080004261-A1 | CGRP receptor antagonists | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-03 | — | — | US | disclosed |
| US-20080004261-A1 | CGRP receptor antagonists | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-03 | — | — | US | disclosed |
| WO-2007146349-A2 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007016087-A2 | HETEROCYCLIC BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070899-A1 | Cgrp Receptor Antagonists | BDKRB1, CCKBR, CALCRL | CALCA 19/4885BACE1 706/4885OPRM1 94/4885 |
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | DPP8, DPP7, AZI2 | CALCA 3165/4885BACE1 3420/4885OPRM1 1519/4885 |
| US-20200172554-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DPP8, DPP7, AZI2 | CALCA 3401/4885BACE1 3511/4885OPRM1 1433/4885 |
| US-20140275017-A1 | CGRP RECEPTOR ANTAGONISTS | BDKRB1, CALCRL, BDKRB2 | CALCA 12/4885BACE1 580/4885OPRM1 34/4885 |
| US-20080113966-A1 | Cgrp Receptor Antagonists | BDKRB1, BDKRB2, CCKBR | CALCA 18/4885BACE1 648/4885OPRM1 85/4885 |
| US-20080004261-A1 | CGRP receptor antagonists | CALCRL, CALCR, GRPR | CALCA 9/4885BACE1 472/4885OPRM1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.